Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline

This is not an original experiment but a systematic review and clinical practice guideline. The authors did not test a single intervention. Instead, they:

**Systematically reviewed** all available published evidence (randomised trials, cohort studies, case series, diagnostic accuracy studies) on the detection, diagnosis, and treatment of primary aldosteronism (PA).

**Formulated recommendations** using the GRADE framework, which grades both the quality of evidence (high, moderate, low, very low) and the strength of recommendations (strong = "recommend" vs. weak = "suggest").

**Compared diagnostic strategies**: case detection using the aldosterone-renin ratio (ARR) vs. no screening; confirmatory testing (oral sodium loading, saline infusion, fludrocortisone suppression, or captopril challenge) vs. no confirmation; adrenal CT vs. adrenal venous sampling (AVS) for subtype differentiation; laparoscopic adrenalectomy vs. medical therapy with mineralocorticoid receptor antagonists (MRAs) for unilateral disease; and MRA therapy vs. no treatment for bilateral disease.

**Outcome measures** included: blood pressure control, resolution of hypokalemia, reduction in cardiovascular events, reduction in left ventricular hypertrophy, improvement in quality of life, and rates of surgical cure.

The guideline is based on a synthesis of multiple studies, not a single population. The evidence base included:

**Case detection studies**: Thousands of hypertensive patients from primary care and specialist hypertension clinics across multiple countries (Italy, Australia, USA, Germany, Japan). Prevalence estimates came from studies ranging from 300 to over 1,000 patients per study.

**Confirmatory test studies**: Several hundred patients with suspected PA, comparing the four recommended confirmatory tests against each other and against the reference standard of response to treatment.

**Subtype testing studies**: Hundreds of patients who underwent both adrenal CT and adrenal venous sampling, with surgical outcome data as the gold standard.

**Treatment outcome studies**: Multiple case series and a few small randomised trials of adrenalectomy vs. medical therapy, involving several hundred patients total, with follow-up ranging from 6 months to 5 years.

**Key populations**: Adults (18–75 years) with hypertension, including those with resistant hypertension (≥3 medications), hypertension with spontaneous or diuretic-induced hypokalemia, hypertension with an adrenal incidentaloma, and those with a family history of early-onset hypertension or stroke.

The guideline did not use a single measurement instrument. Instead, it evaluated the diagnostic accuracy and clinical utility of:

**Aldosterone-renin ratio (ARR)**: Plasma aldosterone concentration (ng/dL) divided by plasma renin activity (ng/mL/h) or direct renin concentration (mU/L). A typical cut-off was >20–30 ng/dL per ng/mL/h, but the guideline emphasised that cut-offs vary by assay and laboratory.

**Confirmatory tests**:

- Oral sodium loading: 24-hour urinary aldosterone >12–14 μg after 3 days of high sodium diet.

- Saline infusion test: Post-infusion plasma aldosterone >5–10 ng/dL.

- Fludrocortisone suppression test: Upright plasma aldosterone >6 ng/dL after 4 days of fludrocortisone and high sodium.

- Captopril challenge test: Plasma aldosterone suppression <30% from baseline after 25–50 mg captopril.

**Subtype imaging**: Adrenal CT with thin-cut (2–3 mm) sections to identify unilateral adenomas vs. bilateral hyperplasia vs. adrenocortical carcinoma.

**Adrenal venous sampling (AVS)**: Cortisol-corrected aldosterone ratio from each adrenal vein. A lateralisation ratio (dominant/non-dominant) >2–4:1 indicated unilateral disease. Success was defined by a cortisol gradient >3:1 between adrenal vein and peripheral vein.

**Treatment outcomes**: Office blood pressure (systolic/diastolic, mmHg), serum potassium (mEq/L), number of antihypertensive medications, and rates of "complete clinical success" (normotension off all medications), "partial success" (same or fewer medications with improved control), and "absent success" (no improvement).

**Study design**: This is a **systematic review and clinical practice guideline**, not a primary study. The Task Force used the GRADE methodology to evaluate the quality of evidence and formulate recommendations.

**Evidence identification**: The authors conducted systematic searches of MEDLINE, EMBASE, and the Cochrane Library from 1966 through 2007. They included randomised controlled trials, prospective cohort studies, retrospective case series, and diagnostic accuracy studies. They did not perform a formal meta-analysis but synthesised findings narratively.

**Grading of evidence**: Each recommendation was assigned a quality of evidence rating:

**High quality**: Further research is very unlikely to change confidence in the estimate of effect.

**Moderate quality**: Further research is likely to have an important impact on confidence.

**Low quality**: Further research is very likely to change the estimate.

**Very low quality**: Any estimate is very uncertain.

**Strength of recommendations**:

**Strong ("recommend")**: The benefits clearly outweigh the harms (or vice versa). Most patients should receive the intervention.

**Weak ("suggest")**: The balance is less certain, or there is more variability in patient values and preferences.

**Consensus process**: The Task Force held one in-person meeting, multiple conference calls, and extensive email correspondence. Drafts were reviewed by The Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and Council, and were posted for public comment on the Society's website.

**What this design can and cannot prove**:

**Can prove**: That a systematic, transparent, evidence-based approach to guideline development was used. That the recommendations reflect the best available evidence at the time. That the strength of each recommendation is explicitly linked to the quality of the underlying evidence.

**Cannot prove**: That any single recommendation is definitively correct. Guidelines are not substitutes for clinical judgment. The evidence base for many recommendations was of low or very low quality (e.g., for confirmatory test thresholds, for the optimal ARR cut-off, for the comparative effectiveness of different MRAs). The guideline cannot prove causality between screening and improved outcomes because no large randomised trial of screening vs. no screening has ever been conducted.

**Major methodological weaknesses**:

**No formal meta-analysis**: The authors did not pool effect sizes across studies, so the precision of estimates is unclear.

**Publication bias**: Studies showing high prevalence or dramatic treatment effects are more likely to be published.

**Outdated evidence**: The guideline was published in 2008. Subsequent research has changed some recommendations (e.g., the role of AVS in younger patients with clear unilateral adenomas on CT).

**Industry funding**: The Task Force received no corporate funding, which is a strength, but the underlying studies they reviewed were often funded by pharmaceutical companies.

**Lack of patient representation**: No patients were included in the guideline development process.

**Prevalence of primary aldosteronism**: Among unselected hypertensive patients, the prevalence was 5–13% (range across studies). In patients with resistant hypertension (≥3 medications), prevalence was 17–23%. In patients with hypertension and hypokalemia, prevalence was 30–50%.

**Case detection using ARR**: The aldosterone-renin ratio had a sensitivity of 73–100% and specificity of 64–100% for detecting PA, depending on the cut-off used and the population. The guideline recommended a cut-off of >20–30 ng/dL per ng/mL/h, but emphasised that this is assay-dependent.

**Confirmatory testing**: All four recommended tests (oral sodium loading, saline infusion, fludrocortisone suppression, captopril challenge) had similar diagnostic accuracy, with sensitivities and specificities in the range of 80–95% when compared against the reference standard of response to treatment. The guideline did not recommend one test over another.

**Subtype testing with CT vs. AVS**: Adrenal CT alone misclassified 37.8% of patients (95% CI: 28–48%) compared to AVS as the gold standard. Specifically, CT incorrectly identified the side of the adenoma in 22% of cases and incorrectly diagnosed bilateral disease when unilateral disease was present in 15% of cases. AVS had a success rate of 70–96% when performed by an experienced radiologist.

**Treatment outcomes for unilateral PA (adrenalectomy)**:

- Complete clinical success (normotension off all medications): 30–60% of patients at 6–12 months post-surgery.

- Partial success (improved blood pressure control with fewer medications): 30–50%.

- Absent success: 5–15%.

- Resolution of hypokalemia: >95% of patients.

- Predictors of complete success: younger age (<40 years), shorter duration of hypertension (<5 years), lower number of antihypertensive medications, and absence of a family history of hypertension.

**Treatment outcomes for bilateral PA (medical therapy)**:

- Spironolactone (25–100 mg/day) reduced systolic blood pressure by 15–25 mmHg and diastolic by 8–12 mmHg on average, with most of the effect seen within 4–8 weeks.

- Eplerenone (50–200 mg/day) had similar efficacy but fewer side effects (less gynecomastia and menstrual irregularities).

- Serum potassium normalised in >90% of patients within 2–4 weeks of starting MRA therapy.

**Cardiovascular outcomes**: Patients with PA had a 2–4 times higher risk of cardiovascular events (stroke, myocardial infarction, atrial fibrillation) compared to age-, sex-, and blood pressure-matched patients with essential hypertension. Treatment (either adrenalectomy or MRA therapy) reduced this risk, but it remained elevated compared to essential hypertensives even after 5 years of follow-up.

**Prevalence**: If you have resistant hypertension (on 3+ medications), there is roughly a 1 in 5 chance that you have primary aldosteronism as the underlying cause. If you also have low potassium, the chance rises to about 1 in 3.

**CT misclassification**: If you rely solely on adrenal CT to decide which adrenal gland is causing the problem, you will be wrong about 38% of the time — meaning nearly 4 out of 10 patients would receive the wrong treatment (either unnecessary surgery or missed opportunity for curative surgery).

**Surgical cure**: About 40–60% of patients with unilateral PA will be cured of hypertension entirely after laparoscopic adrenalectomy. Another 30–50% will need fewer medications. Only 5–15% see no benefit. This means that for every 10 patients who undergo surgery, roughly 5 will be completely off blood pressure medications within a year.

**Blood pressure reduction with medication**: Spironolactone at 50 mg/day typically lowers systolic blood pressure by about 20 mmHg — roughly equivalent to adding a second or third antihypertensive drug. This effect is larger than what is typically seen with other drug classes in resistant hypertension.

**Cardiovascular risk**: Having untreated PA roughly doubles to quadruples your risk of having a heart attack or stroke compared to having essential hypertension with the same blood pressure reading. This means that if your 10-year cardiovascular risk as an essential hypertensive is 10%, having PA might raise it to 20–40%.

**What the authors acknowledge**:

The quality of evidence for most recommendations was low or very low, particularly for diagnostic test thresholds and for the comparative effectiveness of different confirmatory tests.

The optimal ARR cut-off remains uncertain and varies by assay, laboratory, and patient population.

Adrenal venous sampling is technically difficult, invasive, and not widely available. Success rates vary widely between centres.

No large randomised trials have compared screening vs. no screening, or adrenalectomy vs. medical therapy for unilateral PA.

Long-term outcomes beyond 5 years are poorly documented.

**What a critical reader would note**:

**Outdated guideline**: Published in 2008. Subsequent research has shown that ARR screening may be appropriate in a broader population, that AVS may not be necessary in younger patients (<35 years) with a clear unilateral adenoma on CT, and that newer MRAs (e.g., eplerenone) have better side effect profiles.

**Selection bias in prevalence studies**: Many prevalence studies were conducted in specialist hypertension centres, which may overestimate prevalence in the general hypertensive population.

**No cost-effectiveness analysis**: The guideline does not address whether universal screening of all hypertensives is cost-effective.

**Lack of standardisation**: The ARR is affected by many factors (time of day, posture, sodium intake, medications, potassium levels), and the guideline's recommendations for standardisation are detailed but difficult to implement in routine practice.

**Industry funding of underlying studies**: Although the Task Force was independent, many of the studies they reviewed were funded by pharmaceutical companies (e.g., spironolactone and eplerenone manufacturers).

**No patient-reported outcomes**: The guideline focuses on blood pressure and potassium levels, not on quality of life, symptom burden, or patient preferences.

For someone running their own n=1 experiment (with medical supervision — this is not a DIY project):

### What to test

**If you have hypertension** (especially if it's resistant to 2+ medications, or if you have low potassium, or if you have an adrenal mass found incidentally on imaging): Test whether you have primary aldosteronism.

**Specific intervention**: Ask your doctor for a morning blood draw for plasma aldosterone concentration and plasma renin activity (or direct renin concentration) to calculate the aldosterone-renin ratio (ARR). You must be off medications that interfere (spironolactone, eplerenone, amiloride, and some beta-blockers) for 4–6 weeks, and off ACE inhibitors, ARBs, and diuretics for 2 weeks. Your doctor can switch you to medications that don't interfere (e.g., verapamil, hydralazine, prazosin) during this washout period.

**Comparator**: The ARR result compared to the laboratory's cut-off (typically >20–30 ng/dL per ng/mL/h). A positive result should be followed by a confirmatory test (e.g., saline infusion test or oral sodium loading test).

### Minimum meaningful duration

**For case detection**: A single blood draw (morning, after sitting upright for 15–30 minutes, with normal sodium intake). The result is available in 1–2 days.

**For confirmatory testing**: 1–4 days depending on the test (saline infusion takes 4 hours; oral sodium loading takes 3 days).

**For treatment response**: If you are diagnosed with PA and start spironolactone or eplerenone, measure blood pressure and potassium at 2, 4, and 8 weeks. Most of the blood pressure effect appears within 4–8 weeks. If you undergo adrenalectomy, measure blood pressure and potassium at 1, 3, 6, and 12 months post-surgery.

### What to measure

**Primary outcome**: Blood pressure (systolic and diastolic, mmHg) measured at the same time of day, after 5 minutes of seated rest, using a validated home blood pressure monitor. Take 3 readings, 1 minute apart, and average the last 2.

**Secondary outcomes**: Serum potassium (mEq/L), number of antihypertensive medications, and symptoms (headache, fatigue, muscle cramps, palpitations, polyuria).

**For ARR**: Plasma aldosterone (ng/dL) and plasma renin activity (ng/mL/h) or direct renin concentration (mU/L). Calculate the ratio.

-